ABSTRACT
drug that was approved by FDA recently, represents the sole new TB drug developed after the 48 introduction of rifampicin in 1967 (5-7). In this study, by using a whole cell based approach by 
53
The anti-mycobacterial activity was determined by using resazurin reduction microtiter assay 54 (REMA) (8,9). We screened 2538 compounds belonging to three compound libraries namely in case of both the species (Table 1) . In fact, 9 of these compounds exhibited an MIC 99 value of 89 0.5 g/ml or less for both the species indicating their high inhibitory efficacy for these two 90 pathogens ( 
214
In conclusion, we employed a high throughput whole cell screening assay based on the reduction NI -No inhibition of the growth was observed even at the highest concentration of the compound tested 330 (8 g/ml). 331 a -E.coli strains BL-21 (λDE3), XL-1Blue and DH5 were employed and none showed inhibition in the 332 presence of any of the four compounds even at the highest concentration evaluated (8 g/ml). 
